Neoadjuvant Therapy of Targeted Immunotherapy Combined With Chemotherapy for Locally Advanced HNSCC

NCT06699498 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Neoadjuvant Therapy
PD-L1
Anlotinib

Interventions

DRUG: Benmelstobart
DRUG: Anlotinib
DRUG: Cisplatin
DRUG: Paclitaxel for Injection （Albumin Bound）

Sponsor

The First Affiliated Hospital with Nanjing Medical University